REFERENCES

• CarlssonA.The occurrence, distribution and physiological role of catecholamines in the nervous system.Pharmacol Rev.195911(2. Part 2)49049313667431
   PubMed Web of Science ®Google Scholar
• EhringerH.HornykiewiczO.Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system [in German].Klin Wochenschr.1960381236123913726012
   PubMed Web of Science ®Google Scholar
• BernheimerH.BirkmayerW.HornykiewiczO.JellingerK.SeitelbergerF.Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.J Neurol Sci.1973204154554272516
   PubMed Web of Science ®Google Scholar
• HirschE.GraybielAM.AgidYA.Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.Nature.19883343453482899295
   PubMed Web of Science ®Google Scholar
• PolymeropoulosMH.LavedanC.LeroyE.et al.Mutation in the α-synuclein gene identified in families with Parkinson's disease.Science.1997276204520479197268
   PubMed Web of Science ®Google Scholar
• KitadaT.AsakawaS.HattoriN.et al.Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.Nature.19983926056089560156
   PubMed Web of Science ®Google Scholar
• BonifatiV.RizzuP.van BarenMJ.et al.Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonismScience.200329925625912446870
   PubMed Web of Science ®Google Scholar
• LeroyE.BoyerR.AuburgerG.et al.The ubiquitin pathway in Parkinson's disease.Nature.19983954514529774100
   PubMed Web of Science ®Google Scholar
• MaraganoreDM.LesnickTG.ElbazA.et al. UCHL1 is a Parkinson's disease susceptibility gene.Ann Neurol.20045551252115048890
   PubMed Web of Science ®Google Scholar
• KrügerR.KuhnW.MullerT.et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's diseaseNat Genet.1998181061089462735
   PubMed Web of Science ®Google Scholar
• ZarranzJJ.AlegreJ.Gomez-EstebanJC.et al.The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementiaAnn Neurol.20045516417314755719
   PubMed Web of Science ®Google Scholar
• FarrerM.MaraganoreDM.LockhartP.et al.α-Synuclein gene haplotypes are associated with Parkinson's disease.Hum Mol Genet.2001101847185111532993
   PubMed Web of Science ®Google Scholar
• TanEK.TanC.ShenH.et al.Asynuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability.Neurosci Lett.2003336707212493604
   PubMed Web of Science ®Google Scholar
• HolzmannC.KrugerR.SaeckerAM.et al.Polymorphisms of the α-synuclein promoter: expression analyses and association studies in Parkinson's disease.J Neural Transm.2003 110677612541013
   PubMed Web of Science ®Google Scholar
• FarrerM.KachergusJ.FornoL.et al.Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications.Ann Neurol.20045517417914755720
   PubMed Web of Science ®Google Scholar
• SingletonAB.FarrerM.JohnsonJ.et al.α-Synuclein locus triplication causes Parkinson's disease.Science.200330284114593171
   PubMed Web of Science ®Google Scholar
• RockensteinE.HansenLA.MalloryM.et al.Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.Brain Res.2000914485611578596
   PubMed Web of Science ®Google Scholar
• ArimaK.HiraiS.SunoharaN.et al.Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.Brain Res.1999843536110528110
   PubMed Web of Science ®Google Scholar
• BabaM.NakajoS.TuPH.et al.Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.Am J Pathol.19981528798849546347
   PubMed Web of Science ®Google Scholar
• IrizarryMC.GrowdonW.Gomez-lslaT.et al.Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity.J Neuropathol Exp Neurol.1998573343379600226
   PubMed Web of Science ®Google Scholar
• MezeyE.DehejiaAM.HartaG.et al.A synuclein is present in Lewy bodies in sporadic Parkinson's disease.Mol Psychiatry.199834934999857974
   PubMed Web of Science ®Google Scholar
• SpillantiniMG.CrowtherRA.JakesR.et al.α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies.Proc Natl Acad Sci USA.199895646964739600990
   PubMed Web of Science ®Google Scholar
• HillWD.LeeVM.HurtigHI.MurrayJM.TrojanowskiJQ.Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewybodies.J Comp Neurol19913091501601716646
   PubMed Web of Science ®Google Scholar
• IshizawaT.MattilaP.DaviesP.WangD.DicksonDW.Colocalization of tau and α-synuclein epitopes in Lewy bodies.J Neuropathol Exp Neurol.20036238939712722831
   PubMed Web of Science ®Google Scholar
• LoweJ.McDermottH.LandonM.MayerRJ.WilkinsonKD.Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases.J Pathol.19901611531602166150
   PubMed Web of Science ®Google Scholar
• PollanenMS.DicksonDW.BergeronC.Pathology and biology of the Lewy body.J Neuropathol Exp Neurol.199352183191 7684074
   PubMed Web of Science ®Google Scholar
• FornoLS.DeLanneyLE.IrwinI.et al.Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey.Adv Neurol.1996692172288615131
   PubMedGoogle Scholar
• GoodPF.HsuA.WernerP.et al.Protein nitration in Parkinson's disease.J Neuropathol Exp Neurol.1998573383429600227
   PubMed Web of Science ®Google Scholar
• GiassonBl.DudaJE.MurrayIV.et al.Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions.Science.200029098598911062131
   PubMed Web of Science ®Google Scholar
• ShashidharanP.GoodPF.HsuA.et al.TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.Brain Res.200087737938110986355
   PubMed Web of Science ®Google Scholar
• SchlossmacherMG.FroschMP.GaiWP.et al.Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.Am J Pathol.20021601655166712000718
   PubMed Web of Science ®Google Scholar
• MurakamiT.ShojiM.ImaiY.et al.Pael-R is accumulated in Lewy bodies of Parkinson's disease.Ann Neurol.20045543944214991825
   PubMed Web of Science ®Google Scholar
• WakabayashiK.EngelenderS.YoshimotoM.TsujiS.RossCA.TakahashiH.Synphilin-1 is present in Lewy bodies in Parkinson's disease.Ann Neurol.20004752152310762166
   PubMed Web of Science ®Google Scholar
• CortiO.HampeC.KoutnikovaH.et al.The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration.Hum Mol Genet.2003121427143712783850
   PubMed Web of Science ®Google Scholar
• LeeSS.KimYM.JunnE.et al.Cell cycle aberrations by α-synuclein overexpression and cyclin B immunoreactivity in Lewy bodies.Neurobiol Aging .20032468769612885576
   PubMed Web of Science ®Google Scholar
• JunnE.RonchettiRD.QuezadoMM.KimSY.MouradianMM.Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.Proc Natl Acad Sci USA.20031002047205212576551
   PubMed Web of Science ®Google Scholar
• Zarate-LagunesM.GuWJ.BlanchardV.et al.Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in parkinsonian syndromes.J Comp Neurol.200143218419611241385
   PubMed Web of Science ®Google Scholar
• ShimuraH.HattoriN.KuboS.et al.Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.Ann Neurol.19994566867210319893
   PubMed Web of Science ®Google Scholar
• HayashiS.WakabayashiK.IshikawaA.et al.An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene.Mov Disord.20001588488811009195
   PubMed Web of Science ®Google Scholar
• FarrerM.ChanP.ChenR.et al.Lewy bodies and parkinsonism in families with parkin mutations.Ann Neurol.20015029330011558785
   PubMed Web of Science ®Google Scholar
• BandopadhyayR.KingsburyAE.CooksonMR.et al.The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's diseaseBrain.2004127(Pt 2)42043014662519
   PubMed Web of Science ®Google Scholar
• RizzuP.HinkleDA.ZhukarevaV.et al.DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia.Ann Neurol.20045511311814705119
   PubMed Web of Science ®Google Scholar
• ConwayKA.LeeSJ.RochetJC.et al.Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.Proc Natl Acad Sci U SA 200097571576
   PubMed Web of Science ®Google Scholar
• ConwayKA.PchetJC.BieganskiRM.et al.Kinetic stabilization of α-synuclein protofibril by dopamine-α-synuclein adduct.Science.20012941346134911701929
   PubMed Web of Science ®Google Scholar
• TompkinsMM.HillWD.Contribution of somal Lewy bodies to neuronal death.Brain Res.199777524299439824
   PubMed Web of Science ®Google Scholar
• GibbWR.LeesAJ.The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.J Neurol Neurosurg Psychiatry.1988517457522841426
   PubMed Web of Science ®Google Scholar
• GertzHJ.SiegersA.KuchinkeJ.Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease.Brain Res.19946373393418180816
   PubMed Web of Science ®Google Scholar
• PattS.GertzHJ.GerhardL.et al.Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.Histol Histopathol.199163733801725760
   PubMed Web of Science ®Google Scholar
• HillWD.Altered neurofilament expression does not contribute to Lewy body formation.Am J Pathol.19961497287298702011
   PubMedGoogle Scholar
• HartmannA.HunotS.MichelPP.et al.Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.Proc Natl Acad Sci USA.2000972875288010688892
   PubMed Web of Science ®Google Scholar
• HartmannA.HirschEC.Parkinson's disease. The apoptosis hypothesis revisited.Adv Neurol.20018614315311553972
   PubMedGoogle Scholar
• GalvinJE.LeeVM.SchmidtML.TuPH.IwatsuboT.TrojanowskiJQ.Pathobiology of the Lewy body.Adv Neurol.19998031332410410736
   PubMedGoogle Scholar
• TuPH.RobinsonKA.de SnooF.et al.Selective degeneration of Purkinje cells with Lewy body-like inclusions in aged NFHLACZ transgenic mice.J Neurosci.199717106471048994061
   PubMed Web of Science ®Google Scholar
• HurtigHI.TrojanowskiJQ.GalvinJ.et al.α-Synuclein cortical Lewy body correlate with dementia in Parkinson's disease.Neurology.2000541916192110822429
   PubMed Web of Science ®Google Scholar
• MattilaPM.RinneJO.HeleniusH.et al.α-Synuclein-immunoreactive cortical impairment in Parkinson's diseaseActa Neuropathol (Berl).200010028529010965798
   PubMed Web of Science ®Google Scholar
• HirschEC.OrieuxG.MurielMP.FrancoisC.FegerJ.Nondopaminergic neurons in Parkinson's disease.Adv Neurol.200391293712449099
   PubMedGoogle Scholar
• FearnleyJM.LeesAJ.Ageing and Parkinson's disease: substantia nigra regional selectivity.Brain.1991114( Pt 5)228323011933245
   PubMed Web of Science ®Google Scholar
• DamierP.HirschEC.AgidY.GraybielAM.The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.Brain.1999122(Pt 8)1437144810430830
   PubMed Web of Science ®Google Scholar
• DamierP.HirschEC.AgidY.GraybielAM.The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.Brain.1999122(Pt8)1421143610430829
   PubMed Web of Science ®Google Scholar
• GermanDC.ManayeKF.SonsallaPK.et al.Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells.Ann N Y Acad Sci.199264842621353337
   PubMed Web of Science ®Google Scholar
• GasparP.Ben JellounN.FebvretA.Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice.Neuroscience.1994612933057969910
   PubMed Web of Science ®Google Scholar
• LiangCL.SintonCM.GermanDC.Midbrain dopaminergic neurons in the mouse: co- localization with calbindin-D28K and calretinin.Neuroscience.1996755235338931015
   PubMed Web of Science ®Google Scholar
• lacopinoAM.ChristakosS.Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases.Proc Natl Acad Sci USA.199087407840822140897
   PubMed Web of Science ®Google Scholar
• AiraksinenMS.ThoenenH.MeyerM.Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice.Eur J Neurosci.199791201279042576
   PubMed Web of Science ®Google Scholar
• SangheraMK.ManayeK.McMahonA.SonsallaPK.GermanDC.Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP.Neuroreport19978332733319351666
   PubMed Web of Science ®Google Scholar
• UhlGR.Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.Ann Neurol.1998435555609585349
   PubMed Web of Science ®Google Scholar
• MillerGW.EricksonJD.PerezJT.et al.Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.Exp Neurol.199915613814810192785
   PubMed Web of Science ®Google Scholar
• MillerGW.HeilmanCJ.PerezJT.et al.Immunochemical analysis of dopamine transporter protein in Parkinson's disease.Ann Neurol.1997415305399124811
   PubMed Web of Science ®Google Scholar
• ShimadaS.KltayamaS.WaltherD.et al.Dopamine transporter mRNA: dense expression in ventral midbrain neurons.Mol Brain Res.1992133593621352613
   PubMedGoogle Scholar
• UhlGR.WaltherD.MashD.et al.Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.Ann Neurol.1994354944988154880
   PubMed Web of Science ®Google Scholar
• WersingerC.SidhuA.Attentuation of dopamine transporter activity by α-synuclein.Neurosci Lett.200334018919212672538
   PubMed Web of Science ®Google Scholar
• LeeFJ.LiuF.PristupaZB.NiznikHB.Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamineinduced apoptosis.FASEBJ.200115916926
   PubMed Web of Science ®Google Scholar
• LothariusJ.BrundinP.Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein.Nat Rev Neurosci.2002393294212461550
   PubMed Web of Science ®Google Scholar
• VogesD.ZwicklP.BaumeisterW.The 26S proteasome: a molecular machine designed for controlled proteolysis.Annu Rev Biochem.1999681015106810872471
   PubMed Web of Science ®Google Scholar
• AlamZl.DanielSE.LeesAJ.et al.A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.J Neurochem.199769132613299282961
   PubMed Web of Science ®Google Scholar
• McNaughtKS.JennerP.Proteasomal function is impaired in substantia nigra in Parkinson's disease.Neurosci Lett.200129719119411137760
   PubMed Web of Science ®Google Scholar
• McNaughtKS.BelezaireR.Isacson0.et al.Altered proteasomal function in Parkinson's disease.Exp Neurol.2003179384612504866
   PubMed Web of Science ®Google Scholar
• ArdleyHC.ScottGB.RoseSA.TanNG.MarkhamAF.RobinsonPA.Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing parkin.Mol Biol Cell.2003144541455612937272
   PubMed Web of Science ®Google Scholar
• TofarisGK.RazzaqA.GhettiB.LilleyKS.SpillantiniMG.Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.J Biol Cnem.20032784440544411
   Google Scholar
• KastnerA.HirschEC.LejeuneO.Javoy-AgidF.RascolO.AgidY.Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?J Neurochem.199259108010891494900
   PubMed Web of Science ®Google Scholar
• YoritakaA.HattoriN.UchidaK.TanakaM.StadtmanER.MizunoY.Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.Proc Natl Acad Sci USA.199693269627018610103
   PubMed Web of Science ®Google Scholar
• FloorE.WetzelMG.Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.J Neurochem.1998702682759422371
   PubMed Web of Science ®Google Scholar
• KishSJ.MoritoC.HornykiewiczO.Glutathione peroxidase activity in Parkinson's disease brain.Neurosci Lett.1985583433464047494
   PubMed Web of Science ®Google Scholar
• JennerP.DexterDT.SianJ.SchapiraAH.MarsdenCD.Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.Ann Neurol.199232(suppl)S82S871510385
   PubMed Web of Science ®Google Scholar
• DamierP.HirschEC.ZhangP.AgidY.Javoy-AgidF.Glutathione peroxidase, glial cells and Parkinson's disease.Neuroscience.199352168433802
   PubMed Web of Science ®Google Scholar
• DexterDT.CarterCJ.WellsFR.et al.Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.J Neurochem.1989523813892911023
   PubMed Web of Science ®Google Scholar
• ZhangJ.PerryG.SmithMA.et al.Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.Am J Pathol.19991541423142910329595
   PubMed Web of Science ®Google Scholar
• LeeSJ.α-Synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?Antioxid Redox Signal.2003533734812880487
   PubMed Web of Science ®Google Scholar
• HunotS.BruggB.RicardD.et al.Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease.Proc Natl Acad Sci USA.199794753175369207126
   PubMed Web of Science ®Google Scholar
• SoficE.RiedererP.HeinsenH.et al.Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.J Neural Transm.1988741992053210014
   PubMed Web of Science ®Google Scholar
• DexterDT.JennerP.SchapiraAH.MarsdenCD.Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.Ann Neurol.199232(suppl)S94S1001510387
   PubMed Web of Science ®Google Scholar
• FaucheuxBA.MartinME.BeaumontC.HauwJJ.AgidY.HirschEC.Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.J Neurochem.2003861142114812911622
   PubMed Web of Science ®Google Scholar
• KaurD.AndersenJK.Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?Aging Ceil.200211721
   PubMed Web of Science ®Google Scholar
• CastellaniRJ.SiedlakSL.PerryG.SmithMA.Sequestration of iron by Lewy bodies in Parkinson's disease.Acta Neuropathol (Bed).2000100111114
   PubMed Web of Science ®Google Scholar
• GiassonBl.DudaJE.MurrayIV.et al.Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions.Science.200029098598911062131
   PubMed Web of Science ®Google Scholar
• McGeerPL.McGeerEG.Mechanisms of cell death in Alzheimer disease - immunopathology.J Neural Transm Suppl.1998541 59166
   Google Scholar
• McGeerPL.SchwabC.ParentA.DoudetD.Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2,3,6tetrahydropyridine administration.Ann Neurol.20035459960414595649
   PubMed Web of Science ®Google Scholar
• HunotS.HirschEC.Neuroinflammatory processes in Parkinson's disease.Ann Neurol.200353(suppl 3)S49S5812666098
   PubMedGoogle Scholar
• LangstonJW.BallardP.TetrudJW.IrwinI.Chronic parkinsonism in humans due to a product of meperidine-analog synthesis.Science.19832199799806823561
   PubMed Web of Science ®Google Scholar
• LangstonJW.FornoLS.TetrudJ.ReevesAG.KaplanJA.KarlukD.Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.Ann Neurol.19994659860510514096
   PubMed Web of Science ®Google Scholar
• NagatsuT.MogiM.IchinoseH.TogariA.Cytokines in Parkinson's disease.J Neural Transm Suppl.20005814315111128604
   PubMedGoogle Scholar
• BokaG.AngladeP.WallachD.Javoy-AgidF.AgidY.HirschEC.Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.Neurosci Lett.19941721511548084523
   PubMed Web of Science ®Google Scholar
• HunotS.DugasN.FaucheuxB.et al.FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-a in glial cells.J Neurosci.1999193440344710212304
   PubMed Web of Science ®Google Scholar
• HunotS.BoissiereF.FaucheuxB.et al.Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.Neuroscience.1996723553638737406
   PubMed Web of Science ®Google Scholar
• McGeerPL.ItagakiS.AkiyamaH.McGeerEG.Rate of cell death in parkinsonism indicates active neuropathological process.Ann Neurol.1988245745763239957
   PubMed Web of Science ®Google Scholar
• HurleySD.O'BanionMK.SongDD.AranaFS.OlschowkaJA.HaberSN.Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys.Exp Neurol.200318465966814769357
   PubMed Web of Science ®Google Scholar
• BarciaC.BahilloAS.Femandez-VillabaE.et al.Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.Glia.20044640240915095370
   PubMed Web of Science ®Google Scholar
• TattonWG.Chalmers-RedmanR.BrownD.TattonN.Apoptosis in Parkinson's disease: signals for neuronal degradation.Ann Neurol.200353(suppl 3)S61S70 Discussion. S70-S72.12666099
   PubMed Web of Science ®Google Scholar
• KingsburyAE.MardsenCD.FosterOJ.DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?Mov Disord.1998138778849827610
   PubMed Web of Science ®Google Scholar
• GreenDR.Apoptotic pathways: the roads to ruin.Ceil.199894695698
   PubMed Web of Science ®Google Scholar
• HartmannA.Mouatt-PrigentA.VilaM.et al.Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease.Neurobiol Dis.200210283212079401
   PubMed Web of Science ®Google Scholar
• HartmannA.TroadecJD.HunotS.et al.Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.J Neurosci.2001212247225511264300
   PubMed Web of Science ®Google Scholar
• HartmannA.MichelPP.TroadecJD.et al.Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?J Neurochem.2001761785179311259496
   PubMed Web of Science ®Google Scholar
• TattonNA.Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease.Exp Neurol.2000166294311031081
   PubMed Web of Science ®Google Scholar
• HartmannA.Mouatt-PrigentA.FaucheuxBA.AgidY.HirschEC.FADD: a link between TNF family receptors and caspases in Parkinson's disease.Neurology.20025830831011805265
   PubMed Web of Science ®Google Scholar
• HashimotoM.TakedaA.HsuLJ.TakenouchiT.MasliahE.Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease.J Biol Cnem.19992742884928852
   Google Scholar
• SchapiraAH.CooperJM.DexterD.ClarkJB.JennerP.MarsdenCD.Mitochondrial complex I deficiency in Parkinson's disease.J Neurochem.1990548238272154550
   PubMed Web of Science ®Google Scholar
• Di MonteDA.The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?Lancet Neurol.2003253153812941575
   PubMed Web of Science ®Google Scholar
• FlemingL.MannJB.BeanJ.BriggleT.Sanchez-RamosJR.Parkinson's disease and brain levels of organochlorine pesticides.Ann Neurol.1994361001037517654
   PubMed Web of Science ®Google Scholar
• CorriganFM.WienburgCL.ShoreRF.DanielSE.MannD.Qrganochlorine insecticides in substantia nigra in Parkinson's disease.J Toxicol Environ Health A.20005922923410706031
   PubMed Web of Science ®Google Scholar
• CorriganFM.MurrayL.WyattCL.ShoreRF.Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease.Exp Neurol.19981503393429527905
   PubMed Web of Science ®Google Scholar
• CorriganFM.FrenchM.MurrayL.Qrganochlorine compounds in human brain.Hum Exp Toxicol.1996152622648839217
   PubMed Web of Science ®Google Scholar
• UverskyVN.LiJ.FinkAL.Pesticides directly accelerate the rate of asynuclein fibril formation: a possible factor in Parkinson's disease.FEBS Lett.200150010510811445065
   PubMed Web of Science ®Google Scholar
• TakahashiM.YarnadaT.A possible role of influenza A virus infection for Parkinson's disease.Adv Neurol.2001869110411554013
   PubMedGoogle Scholar
• ChapmanG.BeamanBL.LoefflerDA.et al.In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys - and in Lewy body-containing human brain specimens.Exp Neurol.200318471572514769363
   PubMed Web of Science ®Google Scholar
• KennedyPG.Neurovirological methods and their applications.J Neurol Neurosurg Psychiatry.2003741016102212876227
   PubMed Web of Science ®Google Scholar
• RubU.Del TrediciK.SchultzC.et al.Parkinson's disease: the thalamic components of the limbic loop are severely impaired by α-synuclein Immunoposltlve inclusion body pathology.Neurobiol Aging.20022324525411804710
   PubMed Web of Science ®Google Scholar
• EmreM.What causes mental dysfunction in Parkinson's disease?Mov Disord.200318(suppl 6)S63S7114502658
   PubMedGoogle Scholar
• WakabayashiK.TakahashiH.Neuropathology of autonomic nervous system in Parkinson's disease.Eur Neurol.199738(suppl 2)279387796
   PubMed Web of Science ®Google Scholar
• LaiYY.SiegelJM.Physiological and anatomical link between Parkinsonlike disease and REM sleep behavior disorder.Mol Neurobiol.20032713715212777684
   PubMed Web of Science ®Google Scholar
• BraakH.RubU.GaiWP.Del TrediciK.Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.J Neural Transm.200311051753612721813
   PubMed Web of Science ®Google Scholar
• Del TrediciK.RubU.De VosRA.BohlJR.Braak H. Where does Parkinson disease pathology begin in the brain?J Neuropathol Exp Neurol.20026141342612030260
   PubMed Web of Science ®Google Scholar
• BraakH.Del TrediciK.RubU.de VosRA.Jansen SteurEN.BraakE.Staging of brain pathology related to sporadic Parkinson's disease.Neurobiol Aging.20032419721112498954
   PubMed Web of Science ®Google Scholar
• HardyJ.CooksonMR.SingletonA.Genes and parkinsonism.Lancet Neurol.2003222122812849210
   PubMed Web of Science ®Google Scholar
• ChenH.ZhangSM.HernanMA.et al.Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.Arch Neurol.2003601059106412925360
   PubMed Web of Science ®Google Scholar
• MurphyDD.RavinaB.Brain banking for neurodegenerative diseases.Curr Opin Neurol.20031645946312869803
   PubMed Web of Science ®Google Scholar